Veru Inc. (VERU)
NASDAQ: VERU · Real-Time Price · USD
1.185
+0.145 (13.94%)
Jan 23, 2025, 12:29 PM EST - Market open
Veru Inc. Employees
Veru Inc. had 210 employees as of September 30, 2024. The number of employees increased by 21 or 11.11% compared to the previous year.
Employees
210
Change (1Y)
21
Growth (1Y)
11.11%
Revenue / Employee
$80,412
Profits / Employee
-$180,007
Market Cap
174.93M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
VERU News
- 23 days ago - Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business - GlobeNewsWire
- 2 months ago - Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders - GlobeNewsWire
- 2 months ago - Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek - GlobeNewsWire
- 3 months ago - Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss - GlobeNewsWire
- 3 months ago - Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress - GlobeNewsWire
- 4 months ago - Veru to Present at the 2024 Cantor Global Healthcare Conference - GlobeNewsWire
- 5 months ago - Veru Inc. (VERU) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results - GlobeNewsWire